CDP Venture Capital
CDP Venture Capital, established in 2015 and based in Rome, Italy, is a prominent venture capital investment firm dedicated to fostering innovation and economic development within the country. The firm aims to enhance the venture capital ecosystem by investing in startups and growth companies across a diverse range of sectors, including consumer products, energy, healthcare, information technology, automotive, fashion, food, fintech, insur-tech, advanced manufacturing, agriculture materials, education, big data, life sciences, financial services, software-as-a-service, virtual reality, artificial intelligence, and machine learning. By prioritizing these industries, CDP Venture Capital seeks to create sustainable growth and support the overall development of Italy's entrepreneurial landscape.
Top Stages
Past deals in Health Diagnostics
IAMA Therapeutics
Venture Round in 2025
IAMA Therapeutics is a biotechnology company focused on advancing neuroscience drug discovery to develop innovative treatments for children with brain disorders. The company aims to address neurological conditions, offering therapeutic solutions that target learning and memory difficulties associated with Down syndrome and the behavioral challenges linked to autism spectrum disorders. By prioritizing the needs of affected children and their families, IAMA Therapeutics strives to create impactful medicines that improve the quality of life for patients while providing essential support to their families.
GenomeUp
Venture Round in 2025
GenomeUp is a Rome-based healthtech startup that specializes in AI-powered solutions for genetic analysis and clinical decision support. The company aims to serve as a global reference platform to enhance clinical decision-making for hospitals, laboratories, research centers, and pharmaceutical companies. By providing tools that accelerate diagnosis times and improve patient care, GenomeUp seeks to deliver actionable insights for health prevention within a 24-hour timeframe. Emphasizing its commitment to social responsibility, the company has evolved into an Italian Benefit Corporation, prioritizing sustainable and transparent practices that consider the well-being of stakeholders, communities, and the environment.
Salute360
Seed Round in 2025
Salute360 is an online healthcare platform that offers a range of services aimed at enhancing patient access to healthcare. The platform enables patients to book healthcare consultations, order medications, and have them delivered to their homes within hours. Additionally, it facilitates connections between patients and local pharmacists and healthcare professionals, ensuring that necessary healthcare services are readily available and accessible. Through its user-friendly interface, Salute360 strives to provide reliable healthcare information and streamline the process of receiving care, making healthcare more affordable and convenient for its users.
Genoa Instruments
Venture Round in 2025
Genoa Instruments is an innovative startup focused on advancing biomedical and health research through advanced super-resolution optical microscopy. The company has developed a unique microscopy platform that integrates spatial and temporal super-resolution, allowing for structural and functional imaging of living samples with exceptional detail. This platform includes a plug-and-play kit for image-scanning microscopy and next-generation confocal microscopy, enabling researchers to conduct quantitative studies using fluorescence optical microscopy. Genoa Instruments aims to make high-resolution imaging more accessible, thereby fostering scientific discovery and enhancing healthcare research.
EBAMed
Series A in 2025
EBAMed SA is a Swiss startup based in Geneva that specializes in developing innovative medical devices for the non-invasive treatment of heart arrhythmias. Founded in 2018, the company focuses on creating an ultrasound-based device that utilizes proton therapy to monitor heart motion and synchronize therapeutic beams in real time. This technology allows for the precise delivery of radiation treatment to targeted heart tissues, thereby expanding treatment options for existing proton therapy centers and enabling them to treat heart patients effectively. By providing a non-invasive approach to cardiac care, EBAMed aims to improve patient outcomes and streamline treatment processes in outpatient settings.
Restorative Neurotechnologies
Series A in 2024
Restorative Neurotechnologies S.R.L., founded in 2018 and based in Palermo, Italy, specializes in the design and development of non-invasive neuromodulation devices aimed at cognitive rehabilitation. The company focuses on creating innovative medical devices that facilitate cognitive enhancement and rehabilitation for individuals with cognitive impairments, as well as for athletes seeking to improve performance. By providing non-invasive solutions, Restorative Neurotechnologies enables medical professionals to assist both patients and athletes in their recovery and enhancement efforts.
Genespire
Series B in 2024
Genespire is a biotechnology company dedicated to developing innovative gene therapies for patients suffering from genetic diseases, with a particular emphasis on primary immunodeficiencies and inherited metabolic disorders. The company specializes in creating therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for highly effective and adaptable targeted insertion of therapeutic genes into blood cells, providing patients with a range of tailored therapeutic options suited to their specific conditions. By focusing on transformative solutions, Genespire aims to significantly improve the lives of individuals affected by severe genetic disorders.
Aptadir Therapeutics
Pre Seed Round in 2024
Aptadir Therapeutics is a biotechnology company focused on developing novel treatments for diseases associated with abnormal DNA methylation. The company's approach involves using RNA therapeutics to inhibit the function of DNMT1, an enzyme responsible for adding methyl groups to DNA. Specifically, Aptadir is working on a treatment for Myelodysplastic Neoplasms, a group of conditions that affect the blood and bone marrow.
Salute360
Pre Seed Round in 2022
Salute360 is an online healthcare platform that offers a range of services aimed at enhancing patient access to healthcare. The platform enables patients to book healthcare consultations, order medications, and have them delivered to their homes within hours. Additionally, it facilitates connections between patients and local pharmacists and healthcare professionals, ensuring that necessary healthcare services are readily available and accessible. Through its user-friendly interface, Salute360 strives to provide reliable healthcare information and streamline the process of receiving care, making healthcare more affordable and convenient for its users.
Diadem
Venture Round in 2022
Diadem is a biotechnology company focused on developing an innovative blood-based test that utilizes a proprietary antibody targeting a specific conformation of the p53 protein. The company's diagnostic platform aims to predict Alzheimer's disease in its early stages, providing tools for prediction, monitoring, diagnosis, and supporting successful drug development. By offering these capabilities, Diadem enables more cost-effective treatment options for patients with Alzheimer's disease.
Restorative Neurotechnologies
Seed Round in 2020
Restorative Neurotechnologies S.R.L., founded in 2018 and based in Palermo, Italy, specializes in the design and development of non-invasive neuromodulation devices aimed at cognitive rehabilitation. The company focuses on creating innovative medical devices that facilitate cognitive enhancement and rehabilitation for individuals with cognitive impairments, as well as for athletes seeking to improve performance. By providing non-invasive solutions, Restorative Neurotechnologies enables medical professionals to assist both patients and athletes in their recovery and enhancement efforts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.